Linnet Masese1, Jared M Baeten, Barbra A Richardson, Elizabeth Bukusi, Grace John-Stewart, Susan M Graham, Juma Shafi, James Kiarie, Julie Overbaugh, R Scott McClelland. 1. aDepartment of Epidemiology bDepartment of Medicine cDepartment of Global Health dDepartment of Biostatistics eDepartment of Pediatrics, University of Washington, Seattle fVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA gDepartment of Obstetrics and Gynecology hDepartment of Medical Microbiology, University of Nairobi iKenya Medical Research Institute, Nairobi, Kenya jHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kInstitute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.
Abstract
OBJECTIVE: The objective of this study was to understand temporal trends in the contribution of different genital tract infections to HIV incidence over 20 years of follow-up in a cohort of high-risk women. DESIGN: A prospective cohort study. METHODS: We performed monthly evaluations for HIV, vaginal yeast, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, nonspecific cervicitis, herpes simplex virus type two (HSV-2), genital ulcer disease (GUD) and genital warts. We used Cox regression to evaluate the association between sexually transmitted infections (STIs) and HIV acquisition over four time periods (1993-1997, 1998-2002, 2003-2007, 2008-2012). Models were adjusted for age, workplace, sexual risk behaviour, hormonal contraceptive use and other STIs. The resulting hazard ratios were used to calculate population attributable risk percentage (PAR%). RESULTS: Between 1993 and 2012, 1964 women contributed 6135 person-years of follow-up. The overall PAR% for each infection was prevalent HSV-2 (48.3%), incident HSV-2 (4.5%), bacterial vaginosis (15.1%), intermediate microbiota (7.5%), vaginal yeast (6.4%), T. vaginalis (1.1%), N. gonorrhoeae (0.9%), nonspecific cervicitis (0.7%), GUD (0.8%) and genital warts (-0.2%). Across the four time periods, the PAR% for prevalent HSV-2 (40.4%, 61.8%, 58.4%, 48.3%) and bacterial vaginosis (17.1%, 19.5%, 14.7%, 17.1%) remained relatively high and had no significant trend for change over time. The PAR% for trichomoniasis, gonorrhoea, GUD and genital warts remained less than 3% across the four periods. CONCLUSION: Bacterial vaginosis and HSV-2 have consistently been the largest contributors to HIV acquisition risk in the Mombasa Cohort over the past 20 years. Interventions that prevent these conditions would benefit women's health and could reduce their risk of becoming infected with HIV.
OBJECTIVE: The objective of this study was to understand temporal trends in the contribution of different genital tract infections to HIV incidence over 20 years of follow-up in a cohort of high-risk women. DESIGN: A prospective cohort study. METHODS: We performed monthly evaluations for HIV, vaginal yeast, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, nonspecific cervicitis, herpes simplex virus type two (HSV-2), genital ulcer disease (GUD) and genital warts. We used Cox regression to evaluate the association between sexually transmitted infections (STIs) and HIV acquisition over four time periods (1993-1997, 1998-2002, 2003-2007, 2008-2012). Models were adjusted for age, workplace, sexual risk behaviour, hormonal contraceptive use and other STIs. The resulting hazard ratios were used to calculate population attributable risk percentage (PAR%). RESULTS: Between 1993 and 2012, 1964 women contributed 6135 person-years of follow-up. The overall PAR% for each infection was prevalent HSV-2 (48.3%), incident HSV-2 (4.5%), bacterial vaginosis (15.1%), intermediate microbiota (7.5%), vaginal yeast (6.4%), T. vaginalis (1.1%), N. gonorrhoeae (0.9%), nonspecific cervicitis (0.7%), GUD (0.8%) and genital warts (-0.2%). Across the four time periods, the PAR% for prevalent HSV-2 (40.4%, 61.8%, 58.4%, 48.3%) and bacterial vaginosis (17.1%, 19.5%, 14.7%, 17.1%) remained relatively high and had no significant trend for change over time. The PAR% for trichomoniasis, gonorrhoea, GUD and genital warts remained less than 3% across the four periods. CONCLUSION:Bacterial vaginosis and HSV-2 have consistently been the largest contributors to HIV acquisition risk in the Mombasa Cohort over the past 20 years. Interventions that prevent these conditions would benefit women's health and could reduce their risk of becoming infected with HIV.
Authors: R H Gray; M J Wawer; N K Sewankambo; D Serwadda; C Li; L H Moulton; T Lutalo; F Wabwire-Mangen; M P Meehan; S Ahmed; L A Paxton; N Kiwanuka; F Nalugoda; E L Korenromp; T C Quinn Journal: AIDS Date: 1999-10-22 Impact factor: 4.177
Authors: J M Baeten; B A Richardson; H L Martin; P M Nyange; L Lavreys; E N Ngugi; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss Journal: J Acquir Immune Defic Syndr Date: 2000-08-15 Impact factor: 3.731
Authors: Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Walter Jaoko; Juma Shafi; James Kiarie; R Scott McClelland Journal: J Infect Dis Date: 2013-11-22 Impact factor: 5.226
Authors: Michelle C Sabo; Dara A Lehman; Bingjie Wang; Barbra A Richardson; Sujatha Srinivasan; Lusi Osborn; Daniel Matemo; John Kinuthia; Tina L Fiedler; Matthew M Munch; Alison L Drake; David N Fredricks; Julie Overbaugh; Grace John-Stewart; R Scott McClelland; Susan M Graham Journal: Sex Transm Infect Date: 2019-06-13 Impact factor: 3.519
Authors: Kathryn Peebles; Flavia M Kiweewa; Thesla Palanee-Phillips; Catherine Chappell; Devika Singh; Katherine E Bunge; Logashvari Naidoo; Bonus Makanani; Nitesha Jeenarain; Doerieyah Reynolds; Sharon L Hillier; Elizabeth R Brown; Jared M Baeten; Jennifer E Balkus Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: Erica M Lokken; Jennifer E Balkus; James Kiarie; James P Hughes; Walter Jaoko; Patricia A Totten; R Scott McClelland; Lisa E Manhart Journal: Am J Epidemiol Date: 2017-07-15 Impact factor: 4.897
Authors: David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Tarek Hamouda; Derek A Pullum; Gary Cohen; Vira Bitko; Ali Fattom Journal: Vaccine Date: 2019-09-09 Impact factor: 3.641
Authors: Christel Chehoud; Daniel J Stieh; Aubrey G Bailey; Alice L Laughlin; Shannon A Allen; Kerrie L McCotter; Scott A Sherrill-Mix; Thomas J Hope; Frederic D Bushman Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: R Scott McClelland; Jairam R Lingappa; Sujatha Srinivasan; John Kinuthia; Grace C John-Stewart; Walter Jaoko; Barbra A Richardson; Krista Yuhas; Tina L Fiedler; Kishorchandra N Mandaliya; Matthew M Munch; Nelly R Mugo; Craig R Cohen; Jared M Baeten; Connie Celum; Julie Overbaugh; David N Fredricks Journal: Lancet Infect Dis Date: 2018-01-26 Impact factor: 25.071
Authors: Madeleine Heller; Sarah T Roberts; Linnet Masese; Jacquiline Ngina; Neha Chohan; Vrasha Chohan; Juma Shafi; R Scott McClelland; Eleanor Brindle; Susan M Graham Journal: J Womens Health (Larchmt) Date: 2018-04-09 Impact factor: 2.681